H.C. Wainwright upgraded MiNK Therapeutics (INKT) to Buy from Neutral with an unchanged price target of $35 post the Q2 report. The firm sees the company’s Phase 2 gastric cancer data later this year as a “significant catalyst” for the shares. The majority of patients in the Phase 2 gastric study are now enrolled and initial efficacy data is expected in the back half of the year, the analyst tells investors in a research note. H.C. Wainwright points out MiNK shares are now well below its price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics Reports Q2 2025 Milestones and Financials
- MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year
- Mink Therapeutics, Inc. (INKT) Q2 Earnings Cheat Sheet
- H.C. Wainwright downgrades MiNK Therapeutics after 400% rally
- MiNK Therapeutics downgraded to Neutral from Buy at H.C. Wainwright